NYSE:NUVB Nuvation Bio Q1 2025 Earnings Report $2.13 0.00 (0.00%) Closing price 04/25/2025 03:59 PM EasternExtended Trading$2.09 -0.04 (-1.88%) As of 04/25/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Nuvation Bio EPS ResultsActual EPSN/AConsensus EPS -$0.16Beat/MissN/AOne Year Ago EPSN/ANuvation Bio Revenue ResultsActual RevenueN/AExpected Revenue$0.42 millionBeat/MissN/AYoY Revenue GrowthN/ANuvation Bio Announcement DetailsQuarterQ1 2025Date5/7/2025TimeAfter Market ClosesConference Call DateWednesday, May 7, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Nuvation Bio Earnings HeadlinesBrokerages Set Nuvation Bio Inc. (NYSE:NUVB) Price Target at $7.83April 26 at 1:11 AM | americanbankingnews.comNuvation Bio initiated with an Outperform at Citizens JMPApril 24 at 11:18 PM | markets.businessinsider.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 27, 2025 | Paradigm Press (Ad)JMP Securities Initiates Coverage of Nuvation Bio (NUVB) with Market Outperform RecommendationApril 23, 2025 | msn.comNuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025April 22, 2025 | businesswire.comIs Nuvation Bio Inc. (NYSE:NUVB) the Best Biotech Penny Stock to Buy According to Hedge Funds?April 16, 2025 | insidermonkey.comSee More Nuvation Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nuvation Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nuvation Bio and other key companies, straight to your email. Email Address About Nuvation BioNuvation Bio (NYSE:NUVB), a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.View Nuvation Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
